MX2010005863A - Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo. - Google Patents

Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo.

Info

Publication number
MX2010005863A
MX2010005863A MX2010005863A MX2010005863A MX2010005863A MX 2010005863 A MX2010005863 A MX 2010005863A MX 2010005863 A MX2010005863 A MX 2010005863A MX 2010005863 A MX2010005863 A MX 2010005863A MX 2010005863 A MX2010005863 A MX 2010005863A
Authority
MX
Mexico
Prior art keywords
cells
regulatory
vivo expanded
host disease
versus host
Prior art date
Application number
MX2010005863A
Other languages
English (en)
Inventor
Li Li
Tinghua Cao
Original Assignee
Therakos Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therakos Inc filed Critical Therakos Inc
Publication of MX2010005863A publication Critical patent/MX2010005863A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

En la presente especificación se describe un proceso para producir células T reguladoras CD4+CD25+ expandidas ex vivo. El proceso incluye las etapas de extracción de una muestra que incluye células mononucleares sanguíneas periféricas de un donante humano. Las células extraídas incluyen cierta cantidad de células T reguladoras CD4+CD25+. La población relativa de las células T reguladoras CD4+CD25+ mejora de tal manera que fas células Treg constituyen la mayoría de las células en la muestra. Posteriormente, la población de las células Treg enriquecidas, que pueden incluir células Treg derivadas de terceros, se aumenta para producir una población celular clínicamente significativa para su uso en el tratamiento de GVHD.
MX2010005863A 2007-11-30 2008-12-01 Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo. MX2010005863A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99130107P 2007-11-30 2007-11-30
US99234707P 2007-12-05 2007-12-05
PCT/US2008/085117 WO2009073599A1 (en) 2007-11-30 2008-12-01 Process for reducing effects of graft versus host disease using ex vivo expanded cd4+cd25+ regulatory t cells

Publications (1)

Publication Number Publication Date
MX2010005863A true MX2010005863A (es) 2010-06-23

Family

ID=40394411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005863A MX2010005863A (es) 2007-11-30 2008-12-01 Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo.

Country Status (9)

Country Link
US (1) US20090142317A1 (es)
EP (1) EP2225365A1 (es)
JP (1) JP2011505378A (es)
KR (1) KR20100094997A (es)
CN (1) CN101970643A (es)
BR (1) BRPI0819975A2 (es)
CA (1) CA2706458A1 (es)
MX (1) MX2010005863A (es)
WO (1) WO2009073599A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5907357B2 (ja) 2011-10-12 2016-04-26 Ｓｂｉファーマ株式会社 移植臓器生着促進剤
JP6422344B2 (ja) * 2012-03-02 2018-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 同種抗原反応性の制御性ｔ細胞を増大させる方法
WO2013168876A1 (ko) 2012-05-11 2013-11-14 가톨릭대학교 산학협력단 이식 후 면역 상태를 모니터링 하는 키트 및 이를 이용한 면역 상태의 모니터링 방법
WO2014010206A1 (ja) 2012-07-13 2014-01-16 Ｓｂｉファーマ株式会社 免疫寛容誘導剤
WO2015014871A1 (en) * 2013-07-31 2015-02-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits for identifying effector treg cells
KR20180027533A (ko) * 2015-07-03 2018-03-14 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 조절 t 세포를 수득하는 방법 및 이의 용도
EP3216861A1 (en) * 2016-03-11 2017-09-13 Fropharm GmbH Immunoregulatory cells and methods for their production
CN107164324B (zh) * 2017-07-17 2020-03-27 沃昕生物科技(深圳)有限公司 一种脐血Treg细胞的体外扩增方法
JP2021526526A (ja) * 2018-06-14 2021-10-07 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538000A (ja) * 2004-01-08 2007-12-27 リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア 制御性ｔ細胞は自己免疫を抑制する
CA2585462A1 (en) * 2004-10-29 2006-05-11 Benaroya Research Institute At Virginia Mason Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
US8323969B2 (en) * 2007-05-18 2012-12-04 University Of Kansas Preparation of regulatory T cells using ICAM-1 co-stimulation

Also Published As

Publication number Publication date
US20090142317A1 (en) 2009-06-04
CA2706458A1 (en) 2009-06-11
KR20100094997A (ko) 2010-08-27
BRPI0819975A2 (pt) 2015-06-16
WO2009073599A1 (en) 2009-06-11
EP2225365A1 (en) 2010-09-08
CN101970643A (zh) 2011-02-09
JP2011505378A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
MX2010005863A (es) Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo.
TW200637574A (en) Treatment method
MX2009012307A (es) Tratamiento de sinucleinopatias.
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
NZ593208A (en) Cell-scaffold constructs
CA2801536C (en) Protein concentrates and isolates, and processes for the production thereof from macroalgae and/or microalgae
UA99167C2 (ru) Лечение дегенерации межреберных дисков с использованием клеток, полученных из ткани пуповины человека
MX2010005018A (es) Tratamiento de complicaciones de nacimiento prematuro.
MX2007005200A (es) Plaquetas a partir de celulas germinales.
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
EP2732819A3 (en) Compounds that enhance Atoh-1 expression
MX2011007578A (es) Metodos para diagnosticar y tratar la disfagia.
NZ630187A (en) Smooth muscle cell constructs
MX2013006595A (es) Tratamiento de lesion de la medula espinal y lesion traumatica del cerebro empleando celulas madre placentarias.
ATE505533T1 (de) Antigenpräsentierende zellen, verfahren zu ihrer herstellung sowie ihre verwendung für krebsimpfstoffe
WO2011017143A3 (en) Compositions and methods of preparing alloreactive cytotoxic t cells
WO2008055224A3 (en) Lithium stimulation of cord blood stem cell proliferation and growth factor production
IN2014MN01981A (es)
WO2012106367A3 (en) Pluripotent stem cells and method of stimulating and extracting non-embryonic pluripotent stem cells from mammal blood and using reconstituted pluripotent stem cells to treat diseases including chronic obstructive pulmonary disease
WO2012145535A3 (en) Animal model of human cancer and methods of use
WO2012048170A3 (en) Humanized animals via tissue engineering and uses therefor
WO2010144678A3 (en) Generation of vascularized human heart tissue and uses thereof
MX2010003415A (es) Proceso ex vivo, rápido y eficiente para la obtención de células presentadoras de antígenos activadas, útiles para las terapias contra el cáncer y enfermedades relacionadas con el sistema inmunológico.
WO2010135655A3 (en) Human skin substitutes expressing il-12
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов